Rosmarin David, Lofland Jennifer H, Marwaha Simran, Piercy James, Anderson Peter, Liu Jinan
Indiana University School of Medicine, Indianapolis, IN, USA.
Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE, 19803, USA.
Dermatol Ther (Heidelb). 2024 Jun;14(6):1531-1546. doi: 10.1007/s13555-024-01165-5. Epub 2024 May 16.
Vitiligo is a chronic autoimmune disease characterized by destruction of melanocytes, leading to skin depigmentation. Vitiligo can have a high quality-of-life burden and profound impact on psychosocial well-being. The objectives of this study were to describe the self-reported patient burden among patients with nonsegmental vitiligo with ≤ 10% affected body surface area, summarize the physician-reported psychosocial and psychological impact of vitiligo on patient lives, and describe disease characteristics and treatment history, goals, and satisfaction.
Data were drawn from the Adelphi Vitiligo Disease Specific Programme™, a real-world, cross-sectional survey with retrospective data collection of physicians and patients with vitiligo, collected in the United States between October 2021 and April 2022. Separate surveys for dermatologists and patients contained questions on clinical and demographic characteristics of patients with vitiligo and burden of vitiligo. Treatment history, goals, and satisfaction were assessed together with the impact of vitiligo on quality of life.
Sixty-one dermatologists provided data for 326 patients with ≤ 10% affected body surface area (adults, n = 221; adolescents, n = 105); 90 of those patients also responded to the survey. The most common treatments were topical corticosteroids, topical calcineurin inhibitors, and narrow-band ultraviolet-B phototherapy, with the main treatment goal being repigmentation. Physician-reported treatment satisfaction was 56%; 25% of patients reported frustration with treatment options. Physicians reported impact of vitiligo on everyday life in 46% of patients. Patients reported 12.7% overall work impairment; mean scores for Hospital Anxiety and Depression Scale anxiety and depression domains were 3.5 and 2.2, respectively, and mean Vitiligo-specific Quality of Life index score was 26.9. Patients with facial involvement experienced higher burden than those without.
A high patient burden was reported by dermatologists and their patients with vitiligo who had ≤ 10% affected body surface area, including psychosocial and psychological consequences. These findings highlight an unmet need in the treatment of vitiligo.
白癜风是一种慢性自身免疫性疾病，其特征是黑素细胞遭到破坏，导致皮肤色素脱失。白癜风会给患者的生活质量带来沉重负担，并对其心理社会幸福感产生深远影响。本研究的目的是描述非节段型白癜风且体表面积受累≤10%的患者自我报告的负担，总结医生报告的白癜风对患者生活的心理社会和心理影响，并描述疾病特征以及治疗史、目标和满意度。
数据来自阿德尔菲白癜风疾病专项计划™，这是一项现实世界的横断面调查，对白癜风医生和患者进行回顾性数据收集，于2021年10月至2022年4月在美国开展。针对皮肤科医生和患者的单独调查问卷包含有关白癜风患者的临床和人口统计学特征以及白癜风负担的问题。治疗史、目标和满意度与白癜风对生活质量的影响一同进行评估。
61名皮肤科医生为326名体表面积受累≤10%的患者提供了数据（成人221例，青少年105例）；其中90名患者也对调查做出了回应。最常用的治疗方法是外用皮质类固醇、外用钙调神经磷酸酶抑制剂和窄谱中波紫外线光疗，主要治疗目标是色素再生。医生报告的治疗满意度为56%；25%的患者表示对治疗方案感到沮丧。医生报告46%的患者的白癜风对日常生活有影响。患者报告总体工作受损率为12.7%；医院焦虑抑郁量表焦虑和抑郁领域的平均得分分别为3.5和2.2，白癜风特异性生活质量指数平均得分为26.9。面部受累的患者比未受累的患者负担更重。
皮肤科医生及其白癜风患者报告了较高的负担，这些患者体表面积受累≤10%，包括心理社会和心理方面的后果。这些发现凸显了白癜风治疗中未满足的需求。
